Although ZDHHC2 promotes enzalutamide resistance in prostate cancer, the underlying mechanisms remain to be elucidated, so multi‐omics analyses were performed with control and ZDHHC2 knockdown C4‐2 cell lines (Figure 3A). Here, ZDHHC2 is linked to prostate carcinoma.